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Abstract
Multiple myeloma is a hematologic malignancy characterized by a clonal proliferation of plasma cells. PET/MR is
a new emerging hybrid imaging modality, its potential role in numerous different malignant diseases is under
extensive evaluation. Our report describes PET/MR findings of a relapsed multiple myeloma case.
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Introduction
Multiple myeloma (MM) is defined as a malignant proliferation of
plasma cells, principally involving the bone marrow. Disease
expression is very heterogeneous including diffuse bone marrow
infiltration, focal bone destruction or extramedullary lesions [1-4]. The
use of advanced whole body imaging techniques in plasma cell
dyscrasias is supported by growing evidence and guideline inclusions
[5,6]. PET/MR is a new generation hybrid multimodality imaging
technique providing unique opportunity to acquire structural,
functional and metabolic information simultaneously and to overcome
the limitations of each components [7].
Case Report
Multiple myeloma diagnosis was established in January 2015 for a
63 years old female patient (bone marrow: 80% plasma cells; IgA: 45.1
g/l; total serum protein: 115 g/l, SD-IIIB, SPSSIII). 5 cycles of
bortezomib-thalidomide-dexamethasone polichemotherapy regimen
was administered to the patient per protocol, and good partial
response was achieved. After high dose melphalan conditioning
Autologous Stem Cell Transplantation (ASCT) was carried out. 3
months later the ASCT bone marrow aspiration and flow cytometry
were obtained and increased plasma cell fraction was not detectable.
Skeletal radiography did not reveal any osseal myeloma lesion. In June
2016, the patient complained about painful left arm swelling and
referred to PET/MR. Whole body PET/MR examination was
performed on a Siemens Biograph mMR scanner, consisting of a 3.0
Tesla magnet, an actively shielded whole-body gradient coil system,
and an integrated MR compatible lutetium oxyorthosilicate-based
avalanche photodiode containing PET detector system for
simultaneous acquisition. Axial T1 weighted (T1W) Dixon, axial
diffusion weighted (DWI) and coronal Turbo Inversion Recovery
Magnitude (TIRM) sequences were obtained, and simultaneous 3D
PET acquisition after intravenous F18 Fluorodeoxyglucose (FDG)
radiotracer administration was carried out. The examination revealed
multifocal, partly confluent myeloma manifestations along the skeleton
(skull, sternum, ribs, humeral and femoral bones, clavicles, scapulas,
vertebral column, pelvic bones) with low T1 signal intensity and high
signal intensity foci on TIRM and DWI MR Sequences, and pathologic
FDG accumulation on the PET images (Figures 1 and 2). At left
perihumeral location a spacious mass forming soft tissue lesion /
suggested to be extraosseus plasmocytoma/ (Figure 1, red arrow), in
the left distal femoral region - inseparable from the muscles – a smaller
soft tissue focus were also observed (Figure 2, red arrow). Biopsy from
the left femoral soft tissue lesion confirmed plasmocytoma. Based on
the widespread relapse visualized on PET/MR examination and also
confirmed by bone marrow evaluation (25% plasma cells) as a part of
complex oncotherapy palliative external beam radiation was given for
the perihumeral disorder to decrease patient complaints, low dose
cyclophosphamide and dexamethason treatment was administered and
lenalidomide therapy was introduced.
Discussion
Medical imaging is of crucial importance in multiple myeloma.
Whole body MRI and 18F-FDG PET/CT feature the highest sensitivity
for detecting medullary, osseous, soft tissue lesions and organ
manifestations respectively among the established cross-sectional
imaging techniques. MRI has the highest sensitivity for detection of
bone marrow involvement and 18F-FDG PET/CT for detection of
extraosseal lesions [6]. Unlike other multimodality techniques
(SPECT/CT and PET/CT) allowing only sequential imaging
capabilities, PET/MR enables simultaneous and synergistic
multiparametric acquisition. Despite the obvious potential advantages
of PET/MR method its wider clinical penetration is mainly restricted
by low worldwide availability and reimbursement issues. Ongoing
imaging protocol optimization is also a key factor to maximise benefits
in parallel with scanning time reduction [7,8]. The integration of high
potential PET and MR modalities into a “one stop shop” examination
provides unique opportunity to investigate different aspects of MM
pathophysiology and collect complementary biological information
[9].
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Figure 1: Multiple skeletal myeloma manifestations on coronal DWI (A), T1W (B), TIRM (C), Fused PET/TIRM MR (D), PET images (E), and
on 3D Maximal Intensity Projection (MIP) anterior aspect PET dataset (F). Spacious left perihumeral soft tissue mass (red arrow) with
inhomogeneous T1 signal (B), high TIRM signal intensity (C) and intensive FDG accumulation respectively (D-E-F). Upper extremities are
not visualized on the DWI image dataset as a consequence of smaller available MR field of view.
Figure 2: MM manifestations on coronal DWI (A), T1W (B), TIRM (C), Fused PET/TIRM MR (D), PET images (E) and on 3D MIP anterior
aspect PET dataset (F) of the lower extremities. At the medial side of left distal femoral region, among the muscles circumscribed soft tissue
lesion (red arrow) with focal low T1 signal intensity (B), high DWI (A) and TIRM (C) signal intensity and intensive FDG accumulation
respectively (D-E-F).
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